Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor
暂无分享,去创建一个
M. Dowsett | D. Dearnaley | C. Parker | T. Yap | F. Raynaud | J. Bono | G. Attard | Gloria Lee | A. Reid | M. Barrett